October 28, 2026 | BIX 2026 Opens & Korea Makes Moves 🚀

Issue #59 · October 28

View Archive | Subscribe | Partners With Us

From Members to Global: Covering the Entire Bio Industry

BIX Week Is Here! 🤗

Happy Wednesday! BIX 2026 kicks off today at COEX in Seoul, bringing together the global biotech and pharmaceutical community. This week, a $580M licensing deal makes headlines, Korea’s first GLP-1 obesity drug nears launch, and next-generation gene therapy takes the spotlight. Read on for the latest from K-Bio!

🎉 BIOPLUS-INTERPHEX KOREA 2026 — DAY 1!

The opening ceremony has wrapped up successfully, and the event is now in full swing with great enthusiasm and excitement! 🧬✨

Bringing together innovation, collaboration, and the future of the global biohealth industry, the energy here is incredible!

We look forward to welcoming you over the next three days!

💙 More Photo

THIS WEEK:

Korea's first GLP-1 obesity drug Eppe set for Oct. 29 rollout

Eppe, Korea’s first domestically developed glucagon-like peptide-1 (GLP-1) obesity drug, will become available by prescription at some medical institutions starting next Thursday. — Korea JoongAng Daily

Celltrion picks up another Kaigene autoimmune antibody for up to $580.5M

Celltrion has historically been known as a biosimilar maker, with copycat versions of blockbusters Remicade, Rituxan, Humira and others forming the foundation of its business. — Fierce Biotech

‘BIX 2026’ Pre-Registration Closes Today Ahead of a Record-Breaking Edition

This year’s BIX is built around the message “Real Innovation Glows in the Dark,” reflecting the idea that true innovation continues to shine even as the bioindustry navigates challenging times. — THE BIO

KoreaBIO MEMBER NEWS

#Member #Benefits

2026 HR & Labor Relations Training – Session 2

Held on October 27, the program provided practical guidance to HR and labor relations professionals at bio companies, led by labor law experts specializing in the bio industry.

📷 More Photo

2026 K-BIO Accounting Academy – Session 4

Held on October 27, the program focused on revenue accounting and recognition across different sales types, strengthening accounting expertise and fostering networking among bio-industry professionals.

📷 More Photo

Kolmar BioTech Launches Bio-One Infinity, an Execution-Focused Biotech Collaboration Platform

Trial Informatics to Showcase Clinical Trial AI Solutions at TI NEXUS 2026 on November 3

Kolmar BioTech Surveys Demand for Research Space Expansion and Facilities at Lab Cloud

👥 View More Members Companies

Here's what's happening across Korea's bio industry!

WHAT'S HAPPENING

INNOVATION & TRENDS

∎ China Biotech Curbs Could Rattle K-Bio - BusinessKorea
∎ ECM Treatments Boost Willingness to Donate Human Tissue - EDaily
∎ Korean sunscreens go global as Kolmar-Goodai sales hit 100m - The Korea Herald
∎ "One injection on one side, and cancer on the other melted away"... A breakthrough against hard-to-treat cancer with a "30% survival rate" - The Asia Business Daily
∎ Researchers develop heat-triggered microneedle to reduce fertility hormone injections - KBR
∎ “See clearly even when muddy water splashes on the lens”... See-through lens developed - The financial news
∎ WHO chief envisions AI-driven future for global health, hails Korea's vaccine equity push - Korea JoongAng Daily

GROWTH & PERFORMANCE

∎ Bio 'Avengers' Formed... Kolmar Biotech Launches 'Bio-One Infinity' - The financial news
∎ Boryung Signs Space Research MOU With DLR - BusinessKorea
∎ GI Innovation set to collect KRW 4.6 billion in technology fees from Japan’s Maruho for ‘GI-301’ - THE BIO
∎ Genome & Company acquires K-beauty distributor Allbloom to expand US retail presence - KBR
∎ L&C Bio Wins U.S. Patent for Skin ECM-Based Wound Care Technology - Seoul Economic Daily
∎ Medical AI company Lunit will support the development of the next-generation immuno-cancer drug "Ibonesimab" with U.S. bio company Summit Therapeutics. - Maeil Business
∎ Rznomics secures European orphan drug designation for anticancer gene therapy candidate ‘RZ-001’ - THE BIO
∎ Samyang Biopharm, Crosspoint Therapeutics team up to develop next-generation targeted gene therapy - The Herald Business

📰 View Latest KoreaBIO News

WHAT'S WE'VE BEEN UP TO

KoreaBIO participated in ABDD SUMMIT 2026 in Incheon, where Jurie Hwang shared insights on accelerating global market entry and fostering international collaboration in AI-driven biopharmaceutical innovation.

More Photos →